You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.
The prize, organized by the British innovation foundation Nesta, has assembled a series of workshops and support sessions to help prize competitors.
The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.
Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.
In October the company received $15 million in funding from BARDA and venture capital firms to advance its early sepsis detection technology.
The company said the financing brings it a step closer to fulfilling its vision of enabling new-generation tissue analytics tests based on its microfluidic technology.
The funding will support up to 90 percent of development costs for the Klaris system, which purportedly performs phenotypic testing in four hours.
Uppsala University spinout Astrego has developed a system to rapidly detect bacterial infection and antibiotic susceptibility in biofluid.